Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Urovant Sciences, Inc.

https://urovant.com/

Latest From Urovant Sciences, Inc.

Sunovion Plans September Launch For Parkinson’s 'Off' Episode Drug Kynmobi

Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.

Approvals Neurology

Start-Up Quarterly Statistics: Financings Surged In Q4 While M&A Waned

A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.

Deals Financing

Deal Watch: Conatus Ends NASH Ambitions, Merges With Regenerative Medicine Firm Histogen

Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.

Deals M & A

Sumitovant Keeping Sumitomo Dainippon-Acquired Roivant Companies On Track

Scrip spoke with Sumitovant CEO Myrtle Potter about short- and long-term goals for the portfolio of five companies, including Myovant, Urovant and Enzyvant with potential near-term approvals.

Business Strategies Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register